- Report
- March 2025
- 198 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- July 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- November 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- October 2023
- 181 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- December 2019
- 104 Pages
Asia Pacific
From €8585EUR$8,995USD£7,193GBP
- Report
- June 2022
- 215 Pages
United States
From €2576EUR$2,699USD£2,158GBP
- Report
- July 2018
- 224 Pages
Global
From €1288EUR$1,350USD£1,080GBP
€1718EUR$1,800USD£1,439GBP
FluMist Quadrivalent (QIV) is a live attenuated influenza vaccine (LAIV) developed by MedImmune, a subsidiary of AstraZeneca. It is administered as a nasal spray and is approved for use in individuals aged 2-49 years. It is the only LAIV available in the United States and is designed to protect against four strains of influenza virus.
FluMist QIV is a part of the larger vaccine market, which is composed of a variety of products designed to protect against infectious diseases. Vaccines are typically administered to individuals to prevent the spread of disease and to reduce the severity of symptoms. Vaccines are typically administered to individuals through injections, nasal sprays, or oral tablets.
The FluMist QIV market is composed of a variety of companies, including AstraZeneca, MedImmune, Sanofi Pasteur, GlaxoSmithKline, Merck, and Pfizer. These companies are involved in the development, manufacture, and distribution of FluMist QIV. Show Less Read more
